GLP-1 Drugs and Gallbladder Disease: The Cholelithiasis Risk Explained

By Editorial TeamUpdated May 28, 2026

This article is awaiting medical review. Information is editorial only and not a substitute for clinical advice. Our review process.

TL;DR

GLP-1 therapy is associated with a moderately increased risk of gallstone formation (cholelithiasis) and, to a lesser extent, acute inflammation of the gallbladder (cholecystitis).
This is a confirmed adverse drug effect, not just a theoretical signal.
The mechanism: GLP-1 drugs reduce bile acid secretion by decreasing gallbladder contractility; less frequent gallbladder emptying allows bile to become more concentrated and crystalise.
The risk from the underlying obesity and rapid weight loss (independent of the drug) amplifies this — rapid weight loss itself is a strong gallstone risk factor.
In STEP 1 (semaglutide), cholelithiasis occurred in 2.6% of semaglutide patients versus 1.2% placebo.
In SCALE Obesity (liraglutide), the rate was higher.
Patients who develop abdominal symptoms consistent with gallstone disease (right upper quadrant pain, particularly postprandial) while on GLP-1 therapy should seek evaluation.

A teal gallbladder glyph with a small orange stone, illustrating gallbladder risk on GLP-1 drugs. — Fast weight loss itself raises the gallstone odds.

Gallbladder disease is one of the better-established adverse effects of GLP-1 therapy — the human evidence is stronger than for some other GLP-1 risks, the mechanism is understood, and the clinical data is consistent across drug classes.

This article awaits medical-reviewer signoff.

The mechanism

GLP-1 receptors are expressed on gallbladder smooth muscle cells. GLP-1 agonism reduces gallbladder motility — the gallbladder contracts less frequently and empties less completely.

Bile stasis and crystallisation: Normal gallbladder function requires periodic emptying to prevent bile from becoming overly concentrated. Reduced gallbladder motility allows bile to pool and concentrate. Cholesterol crystals form in concentrated bile; these aggregate into gallstones over time.

Rapid weight loss amplifier: GLP-1 therapy produces significant weight loss, and rapid weight loss itself is a well-established gallstone risk factor — independent of any drug effect. During rapid fat mobilisation, increased cholesterol secretion into bile further promotes crystallisation. The GLP-1 drug effect and the weight-loss effect are additive.

The clinical data

STEP 1 (Wegovy/semaglutide, 68 weeks)

Event	Semaglutide 2.4 mg	Placebo
Cholelithiasis (gallstones)	2.6%	1.2%
Cholecystitis	0.8%	0.4%

The doubling of cholelithiasis rate is statistically significant and consistent with the proposed mechanism.

SCALE Obesity (Saxenda/liraglutide, 56 weeks)

Liraglutide-treated patients showed higher rates of cholelithiasis than placebo — approximately 2.5x the rate in some analyses. The signal appeared earlier in the course of treatment than with semaglutide in some comparisons.

SURMOUNT trials (tirzepatide)

Tirzepatide trials also showed elevated cholelithiasis rates in the active treatment arm versus placebo. The signal is consistent across GLP-1 drug classes.

Tirzepatide at higher doses

Greater weight loss at higher tirzepatide doses is associated with higher absolute gallstone rates — consistent with the weight-loss-mediated component of the mechanism.

Who is at higher baseline risk

Gallstone risk factors that amplify the GLP-1 effect:

Female sex: Women have 2–3x the baseline gallstone risk of men
Obesity: Baseline risk for gallstone disease is elevated in obesity — the population using these drugs
Prior gallstone history: Prior gallstone episodes signal gallbladder disease susceptibility
Rapid weight loss: Faster weight loss (more achievable with GLP-1 therapy than diet alone) is associated with proportionally higher gallstone risk during the loss phase
High-fat diet changes: Dramatic shifts in dietary pattern affect bile composition

Symptoms to watch for

Gallstone disease can present as:

Biliary colic: Intermittent, severe right upper quadrant or epigastric pain, typically occurring 30–60 minutes after eating (particularly fatty meals). Lasts minutes to hours. May radiate to the right shoulder or back. Resolves spontaneously.

Acute cholecystitis: Persistent right upper quadrant pain (not intermittent), fever, tenderness on abdominal examination. Represents gallbladder inflammation from a stone obstructing the cystic duct. Requires medical evaluation; often treated with cholecystectomy.

Choledocholithiasis / cholangitis: If a gallstone moves into the common bile duct, it can cause jaundice, dark urine, and signs of biliary obstruction. Requires urgent evaluation.

Any new abdominal pain — particularly right upper quadrant or postprandial — in a patient on GLP-1 therapy should prompt evaluation rather than attribution to the drug's standard GI side effects.

Clinical management

For patients with no gallstone history: Standard monitoring (reporting symptoms); no routine gallbladder imaging is specified in the labels.

For patients with prior gallstone history or gallbladder disease: This is a clinical risk-benefit discussion with the prescriber. Patients who have already had a cholecystectomy (gallbladder removed) cannot develop cholecystitis or cholelithiasis and do not carry this risk. Patients with an intact gallbladder and prior stones need individual assessment.

If gallstones are detected: The clinical decision about whether to continue GLP-1 therapy when asymptomatic gallstones are incidentally discovered is individualised. Asymptomatic gallstones are common in the general population; discovery does not automatically require stopping the drug.

If symptomatic gallstone disease develops: Clinical management follows standard gallbladder protocols. GLP-1 discontinuation decisions depend on the severity and whether surgical management is planned.

Editorial note: This article awaits medical-reviewer signoff. Gallbladder risk is an established GLP-1 class effect. Discuss your personal gallbladder history with your prescriber before starting a GLP-1 drug, and report any new abdominal pain — particularly right upper quadrant pain occurring after meals — promptly.

Frequently asked questions

Do GLP-1 drugs cause gallstones?

Yes — there is a confirmed association between GLP-1 therapy and increased gallstone formation. In STEP 1 (Wegovy pivotal trial), cholelithiasis occurred in 2.6% of semaglutide patients versus 1.2% of placebo patients. The mechanism involves reduced gallbladder motility from GLP-1 agonism, leading to bile stasis and increased crystal formation. Rapid weight loss from GLP-1 therapy also independently increases gallstone risk. This page awaits medical reviewer signoff.

What symptoms suggest gallbladder problems on GLP-1 therapy?

Gallstone symptoms typically include right upper quadrant or epigastric pain, often occurring after fatty meals (postprandial). The pain can be severe and colicky (biliary colic) or, if the gallstone causes acute cholecystitis, persistent and associated with fever and tenderness. Any new abdominal pain — particularly right upper quadrant — in a patient on GLP-1 therapy warrants evaluation.

Should people with a history of gallstones avoid GLP-1 drugs?

A history of gallstones is not an absolute contraindication to GLP-1 therapy, but it is a relevant clinical factor for the prescriber to weigh. Patients with prior symptomatic gallstone disease who are considering GLP-1 therapy should discuss the gallbladder risk explicitly. The decision depends on whether the gallbladder has been removed (cholecystectomy), the severity of prior episodes, and the overall clinical picture.